Drug Profile
Filgrastim biosimilar - Cerbios Pharma
Alternative Names: Recombinant granulocyte-colony stimulating factor - Cerbios-PharmaLatest Information Update: 12 Nov 2021
Price :
$50
*
At a glance
- Originator Cerbios-Pharma
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Neuroprotectants; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for preclinical development in Neutropenia in Switzerland
- 17 Jun 2015 Preclinical trials in Neutropenia in Switzerland (unspecified route) (Cerbios-Pharma website, May 2015)